These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 33860365)

  • 21. VIP-SPOT: an Innovative Assay To Quantify the Productive HIV-1 Reservoir in the Monitoring of Cure Strategies.
    Puertas MC; Bayón-Gil Á; Garcia-Guerrero MC; Salgado M; Urrea V; Morón-López S; Peña R; Jiménez-Moyano E; Clotet B; Prado JG; Martinez-Picado J
    mBio; 2021 Jun; 12(3):e0056021. PubMed ID: 34154408
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Humanized Mouse Model of HIV-1 Latency with Enrichment of Latent Virus in PD-1
    Llewellyn GN; Seclén E; Wietgrefe S; Liu S; Chateau M; Pei H; Perkey K; Marsden MD; Hinkley SJ; Paschon DE; Holmes MC; Zack JA; Louie SG; Haase AT; Cannon PM
    J Virol; 2019 May; 93(10):. PubMed ID: 30842333
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stable Phenotypic Changes of the Host T Cells Are Essential to the Long-Term Stability of Latent HIV-1 Infection.
    Seu L; Sabbaj S; Duverger A; Wagner F; Anderson JC; Davies E; Wolschendorf F; Willey CD; Saag MS; Goepfert P; Kutsch O
    J Virol; 2015 Jul; 89(13):6656-72. PubMed ID: 25878110
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV-1 reservoir dynamics in CD4+ T cells.
    Bruner KM; Cohn LB
    Curr Opin HIV AIDS; 2019 Mar; 14(2):108-114. PubMed ID: 30531293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV Replication and Latency in a Humanized NSG Mouse Model during Suppressive Oral Combinational Antiretroviral Therapy.
    Satheesan S; Li H; Burnett JC; Takahashi M; Li S; Wu SX; Synold TW; Rossi JJ; Zhou J
    J Virol; 2018 Apr; 92(7):. PubMed ID: 29343582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibody-Mediated CD4 Depletion Induces Homeostatic CD4
    Kumar NA; McBrien JB; Carnathan DG; Mavigner M; Mattingly C; White ER; Viviano F; Bosinger SE; Chahroudi A; Silvestri G; Paiardini M; Vanderford TH
    J Virol; 2018 Nov; 92(22):. PubMed ID: 30185596
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Latently infected cell activation: a way to reduce the size of the HIV reservoir?
    Forde J; Volpe JM; Ciupe SM
    Bull Math Biol; 2012 Jul; 74(7):1651-72. PubMed ID: 22562387
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Toll-Like Receptor 7 Agonist GS-9620 Induces HIV Expression and HIV-Specific Immunity in Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy.
    Tsai A; Irrinki A; Kaur J; Cihlar T; Kukolj G; Sloan DD; Murry JP
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28179531
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of HIV latent infection model with multiple infection stages and different drug classes.
    Alshorman A; Al-Hosainat N; Jackson T
    J Biol Dyn; 2022 Dec; 16(1):713-732. PubMed ID: 36264087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stochastic Dynamics of the Latently Infected Cell Reservoir During HIV Infection.
    Azoz SA; Coombs D
    Bull Math Biol; 2019 Jan; 81(1):131-154. PubMed ID: 30298198
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Th1/17 Polarization of CD4 T Cells Supports HIV-1 Persistence during Antiretroviral Therapy.
    Sun H; Kim D; Li X; Kiselinova M; Ouyang Z; Vandekerckhove L; Shang H; Rosenberg ES; Yu XG; Lichterfeld M
    J Virol; 2015 Nov; 89(22):11284-93. PubMed ID: 26339043
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mathematical Models of HIV Latency.
    Hill AL
    Curr Top Microbiol Immunol; 2018; 417():131-156. PubMed ID: 29164341
    [TBL] [Abstract][Full Text] [Related]  

  • 33. From reactivation of latent HIV-1 to elimination of the latent reservoir: the presence of multiple barriers to viral eradication.
    Shan L; Siliciano RF
    Bioessays; 2013 Jun; 35(6):544-52. PubMed ID: 23613347
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV infection dynamics and viral rebound: Modeling results from humanized mice.
    Guo T; Deng Q; Qiu Z; Rong L
    J Theor Biol; 2023 Jun; 567():111490. PubMed ID: 37054969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure.
    Ruff CT; Ray SC; Kwon P; Zinn R; Pendleton A; Hutton N; Ashworth R; Gange S; Quinn TC; Siliciano RF; Persaud D
    J Virol; 2002 Sep; 76(18):9481-92. PubMed ID: 12186930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Infection with a newly designed dual fluorescent reporter HIV-1 effectively identifies latently infected CD4
    Cai J; Gao H; Zhao J; Hu S; Liang X; Yang Y; Dai Z; Hong Z; Deng K
    Elife; 2021 Apr; 10():. PubMed ID: 33835029
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short Intracellular HIV-1 Transcripts as Biomarkers of Residual Immune Activation in Patients on Antiretroviral Therapy.
    Ishizaka A; Sato H; Nakamura H; Koga M; Kikuchi T; Hosoya N; Koibuchi T; Nomoto A; Kawana-Tachikawa A; Mizutani T
    J Virol; 2016 Jun; 90(12):5665-5676. PubMed ID: 27030274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Pathway To Establishing HIV Latency Is Critical to How Latency Is Maintained and Reversed.
    Rezaei SD; Lu HK; Chang JJ; Rhodes A; Lewin SR; Cameron PU
    J Virol; 2018 Jul; 92(13):. PubMed ID: 29643247
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An HIV model with age-structured latently infected cells.
    Alshorman A; Samarasinghe C; Lu W; Rong L
    J Biol Dyn; 2017 Mar; 11(sup1):192-215. PubMed ID: 27338168
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.